眼弓形虫病的当前管理实践
国际眼弓形虫病研究组对48个国家192名葡萄膜炎专科眼科医生进行36项问卷调查,了解眼弓形虫病的临床特征、检查使用、治疗指征、全身及玻璃体内抗寄生虫药与糖皮质激素治疗、随访和预防性治疗。结果显示典型表现为色素瘢痕邻近的单侧视网膜脉络膜炎,口服甲氧苄啶-磺胺甲噁唑为多数成员的一线治疗,糖皮质激素全身给药常见,部分成员对选定患者进行预防性治疗。
要点
- 77.1%成员报告超过60%的表现为色素瘢痕邻近的单侧视网膜脉络膜炎,但也有多种非典型表现。
- 66.7%成员将口服甲氧苄啶-磺胺甲噁唑作为一线治疗,60.9%有玻璃体内克林霉素使用经验。
- 97.4%成员全身使用糖皮质激素,24.7%同时玻璃体内注射糖皮质激素,几乎总是联合抗微生物药(72.3%)。
核心结论
- 本报告呈现了大型国际葡萄膜炎专科眼科医生群体当前对眼弓形虫病的管理方法。
研究设计与样本
- 2020年11月国际眼弓形虫病研究组由葡萄膜炎专科眼科医生组成,来自48个国家的192名成员完成36项问卷调查。
主要发现
- 77.1%成员报告色素瘢痕邻近的单侧视网膜脉络膜炎占其表现超过60%,但也报告了多种非典型表现。
- 常见并发症包括持续性玻璃体混浊、视网膜前膜、白内障以及眼压升高或青光眼。
- 大多数成员使用临床检查联合血清学(56.8%)或不联合血清学(35.9%)诊断典型疾病,非典型病例依赖眼内液检测通常为PCR(68.8%)。
- 66.1%成员治疗所有非妊娠患者,33.9%治疗选定患者。
- 口服甲氧苄啶-磺胺甲噁唑是66.7%成员的一线治疗,60.9%有玻璃体内克林霉素使用经验。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Ocular toxoplasmosis is common across all regions of the world. Understanding of the epidemiology and approach to diagnosis and treatment have evolved recently. In November 2020, an international group of uveitis-specialised ophthalmologists formed the International Ocular Toxoplasmosis Study Group to define current practice. METHODS: 192 Study Group members from 48 countries completed a 36-item survey on clinical features, use of investigations, indications for treatment, systemic and intravitreal treatment with antiparasitic drugs and corticosteroids, and approach to follow-up and preventive therapy. RESULTS: For 77.1% of members, unilateral retinochoroiditis adjacent to a pigmented scar accounted for over 60% of presentations, but diverse atypical presentations were also reported. Common complications included persistent vitreous opacities, epiretinal membrane, cataract, and ocular hypertension or glaucoma. Most members used clinical examination with (56.8%) or without (35.9%) serology to diagnose typical disease but relied on intraocular fluid testing-usually PCR-in atypical cases (68.8%). 66.1% of members treated all non-pregnant patients, while 33.9% treated selected patients. Oral trimethoprim-sulfamethoxazole was first-line therapy for 66.7% of members, and 60.9% had experience using intravitreal clindamycin. Corticosteroid drugs were administered systemically by 97.4%; 24.7% also injected corticosteroid intravitreally, almost always in combination with an antimicrobial drug (72.3%). The majority of members followed up all (60.4%) or selected (35.9%) patients after resolution of acute disease, and prophylaxis against recurrence with trimethoprim-sulfamethoxazole was prescribed to selected patients by 69.8%. CONCLUSION: Our report presents a current management approach for ocular toxoplasmosis, as practised by a large international group of uveitis-specialised ophthalmologists.
引用
- Yogeswaran K, Furtado JM, Bodaghi B, et al. Current practice in the management of ocular toxoplasmosis. Br J Ophthalmol. 2022. PMID: 35197262. doi:10.1136/bjophthalmol-2022-321091
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。